Research Analysts’ Weekly Ratings Changes for Insulet (PODD)

Several analysts have recently updated their ratings and price targets for Insulet (NASDAQ: PODD):

• 11/11/2024 – Insulet had its price target raised by analysts at Morgan Stanley from $234.00 to $317.00. They now have an “overweight” rating on the stock.
• 11/11/2024 – Insulet had its price target raised by analysts at Barclays PLC from $220.00 to $234.00. They now have an “equal weight” rating on the stock.
• 11/8/2024 – Insulet had its price target raised by analysts at BTIG Research from $260.00 to $270.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Insulet is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $300.00 price target on the stock.
• 10/14/2024 – Insulet had its price target raised by analysts at Raymond James from $213.00 to $260.00. They now have an “outperform” rating on the stock.
• 10/14/2024 – Insulet had its price target raised by analysts at BTIG Research from $250.00 to $260.00. They now have a “buy” rating on the stock.
• 10/1/2024 – Insulet had its price target raised by analysts at Citigroup Inc. from $250.00 to $275.00. They now have a “buy” rating on the stock.
• 9/25/2024 – Insulet had its price target raised by analysts at Canaccord Genuity Group Inc. from $236.00 to $269.00. They now have a “buy” rating on the stock.
• 9/17/2024 – Insulet had its price target raised by analysts at Piper Sandler from $230.00 to $285.00. They now have an “overweight” rating on the stock.

Insulet Stock Performance

Shares of PODD stock opened at $269.06 on Thursday. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The firm’s 50-day simple moving average is $235.96 and its two-hundred day simple moving average is $206.47. The firm has a market cap of $18.87 billion, a price-to-earnings ratio of 46.07, a P/E/G ratio of 4.26 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Hedge Funds Weigh In On Insulet

Several institutional investors have recently bought and sold shares of PODD. Blue Trust Inc. boosted its position in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in Insulet in the 2nd quarter worth approximately $32,000. Venturi Wealth Management LLC grew its stake in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares in the last quarter. UMB Bank n.a. raised its holdings in Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the period. Finally, CVA Family Office LLC lifted its position in shares of Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 145 shares in the last quarter.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.